Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23347868 | 0.81 | — | — | |
| SCHEMBL22000950 | 0.80 | HRH3 (0.31) | SIGMAR1 | |
| SCHEMBL21316728 | 0.80 | MEN1 (0.45) | — | |
| SCHEMBL22000949 | 0.79 | SMN1; SMN2 (0.33) | — | |
| SCHEMBL23347870 | 0.79 | MEN1 (0.44) | — | |
| SCHEMBL22001603 | 0.79 | KDM4E (0.32) | — | |
| SCHEMBL408739 | 0.78 | SIGMAR1 (0.31) | SIGMAR1 | |
| SCHEMBL23347611 | 0.77 | SIGMAR1 (0.30) | SIGMAR1 | |
| SCHEMBL22001203 | 0.75 | — | — | |
| SCHEMBL23347753 | 0.74 | HRH3 (0.32) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11071749-B2 | Oligonucleotide analogues targeting human LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-20200147119-A1 | OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2020-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11071749-B2 | Oligonucleotide analogues targeting human LMNA | LMNB2, LMNA, LMNB1 | SIGMAR1 3742/4885 |
| US-20200147119-A1 | OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | LMNB2, LMNA, LMNB1 | SIGMAR1 3742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.